Emerging Biostocks


Biotechnology companies’ fortunes depend on binary events, such as FDA approvals and clinical trials results. Drugs, devices, etc. either work or fail – with huge implications for the stock price.

This volatility opens the door to big profits, particularly in the mid or small cap part of the sector. However, capitalizing on these opportunities depends on knowing when the key events are going to happen.

Given there are thousands of events that can impact biotech stocks, it is difficult for individual investors and traders to keep track of all the potential regulatory and clinical catalysts. This can result in easily missing out on some extraordinary investment opportunities. This is where the RTT Biotech Stocks service can help both novice and professional investors stay ahead of the markets.

RTT tracks and monitors hundreds of companies and potential market-moving events. These include such things as pending new drug approvals, new FDA submissions, pending mid/early-stage clinical trial results, late-stage phase 3 clinical trial results, FDA advisory panel meetings and much more. The RTT Biotech Stock service alerts users ahead of key events, enabling our subscribers to take advantage of the opportunities.

Top Performers
Pub. DateCompany% Gain
06/03/2013 ARWR + 1144.60
05/15/2013 BCRX + 754.97
01/16/2013 GALT + 676.83
06/14/2013 PBYI + 661.85
03/18/2013 INO + 631.48
06/19/2013 TKMR + 566.95
06/05/2013 CRMD + 471.43
06/11/2013 PRAN + 463.14
08/22/2013 IDIX + 442.04
01/04/2013 ALIM + 399.41

Sign up today for your FREE 30 days trial, and let us help you find the best biotech investment opportunities. This offer is 100% RISK-FREE. If you are satisfied with the service after the 30 day trial, continue using the service at just $50/month.

Our premium service gives biotech investors the edge they need to make their investments and trades more successful by discovering overlooked and undervalued pharmaceutical and health-care opportunities long before they come to the attention of the general investing public.

Although past performance is not indicative of future results, the average of all biotech stocks we have profiled over the last two years have yielded an average of 60% gains, with many yielding triple digit gains.

Here’s how some of our recent winners have fared:
  • ZLTQ was trading around $15.21 when we alerted our readers on July 17, 2014. The stock logged in a gain of over 45% in less than 2 weeks.

  • Our alert on AERI was published on March 25, 2014 when it was trading around $20. The stock touched an all-time high of $29.71 on June 25, representing a gain of over 47% in 3 months.

  • EGRX was trading around $9 when we alerted our readers on May 23, 2014, and in just a little over two months, the stock returned a maximum gain of 57%.

  • Another stock pick worth mentioning is PCRX. We alerted this stock to our readers on April 28, 2014 at around $63 and it touched a high of $94.30 on July 1, which equates to a gain of 48%.

  • We profiled LJPC on February 25, 2014 when we speculated that positive phase II results of its kidney drug could drive the stock price higher. The stock touched a high of $19.50 on March 11, following the announcement of the trial results, reflecting a gain of 156%, about 2 weeks after our alert.

Check our complete performance to see our track record.


With your subscription you will receive:
  • Email alert whenever we publish a report on an upcoming event
  • Access to all previous reports and comprehensive performance details
  • Week ahead briefing - details of all the key events to look for in the week ahead

signup



 

All of the free and premium services offered on RTTNews.com are provided for information purposes only. None of the information or opinions expressed in any of our services should be construed as an offer or solicitation to buy or sell, or as an endorsement, recommendation of any securities, options, futures or funds. We are not investment advisors and we do not provide personalized advice. If you need personal advice, then you should seek the advice of a qualified investment advisor.

All our services are designed to help you save time with your investment research. RTTNews does not warrant the reliability or completeness or accuracy of the Content found in our Services or its usefulness for any particular purpose. You are responsible for your own investment decisions. RTTNews will not be liable for any direct, indirect, incidental or any other type of loss or damages caused by a reader's reliance on information obtained on our site.

Please read our Terms and Conditions of service for complete terms.

Last Update on 07/31/2014